{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:39Z","timestamp":1787721639866,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.7759\/cureus.115189","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:25:47Z","timestamp":1787718347000},"source":"Crossref","is-referenced-by-count":0,"title":["Prescription Trends in the Management of Lower Urinary Tract Symptoms in Men: An Online Survey of Indian Urologists"],"prefix":"10.7759","author":[{"given":"Prakash","family":"Patwardhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Palkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhra","family":"Dhurandhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cont.2024.101320","article-title":"Storage-dominant lower urinary tract symptoms in the older male: practical approach, guidelines recommendations and limitations of evidence","volume":"11","author":"Sinha S","year":"2024","unstructured":"Sinha S, Cameron AP, Tse V, Panicker J. Storage-dominant lower urinary tract symptoms in the older male: practical approach, guidelines recommendations and limitations of evidence. Continence. 2024, 11:101320. 10.1016\/j.cont.2024.101320","journal-title":"Continence"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06628-8","article-title":"The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"7","author":"Lee SW","year":"2017","unstructured":"Lee SW, Chan EM, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017, 7:7984. 10.1038\/s41598-017-06628-8","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.747144","article-title":"Overactive bladder symptoms within nervous system: a focus on etiology","volume":"12","author":"Qin C","year":"2021","unstructured":"Qin C, Wang Y, Gao Y. Overactive bladder symptoms within nervous system: a focus on etiology. Front Physiol. 2021, 12:747144. 10.3389\/fphys.2021.747144","journal-title":"Front Physiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-112138","article-title":"Prevalence and factors associated with lower urinary tract symptoms suggestive of benign prostatic hyperplasia among men aged 50 years and above in Coimbatore district, Tamil Nadu, India: a community-based cross-sectional study","volume":"16","author":"Pandi BN","year":"2026","unstructured":"Pandi BN, George S, Olickal JJ, Thankappan KR. Prevalence and factors associated with lower urinary tract symptoms suggestive of benign prostatic hyperplasia among men aged 50 years and above in Coimbatore district, Tamil Nadu, India: a community-based cross-sectional study. BMJ Open. 2026, 16:e112138. 10.1136\/bmjopen-2025-112138","journal-title":"BMJ Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.05.008","article-title":"An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine","volume":"9","author":"Bhat SA","year":"2022","unstructured":"Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. Asian J Urol. 2022, 9:109-18. 10.1016\/j.ajur.2021.05.008","journal-title":"Asian J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.019","article-title":"What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women","volume":"65","author":"Agarwal A","year":"2014","unstructured":"Agarwal A, Eryuzlu LN, Cartwright R, et al.. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014, 65:1211-7. 10.1016\/j.eururo.2014.01.019","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023","volume":"211","author":"Sandhu JS","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024, 211:11-9. 10.1097\/JU.0000000000003698","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas S","year":"2023","unstructured":"Gravas S, Gacci M, Gratzke C, et al.. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol. 2023, 84:207-22. 10.1016\/j.eururo.2023.04.008","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_121_21","article-title":"The Urological Society of India guidelines on management of benign prostatic hyperplasia\/benign prostatic obstruction (executive summary)","volume":"37","author":"Sabnis RB","year":"2021","unstructured":"Sabnis RB, Mulawkar PM, Joshi RN. The Urological Society of India guidelines on management of benign prostatic hyperplasia\/benign prostatic obstruction (executive summary). Indian J Urol. 2021, 37:210-3. 10.4103\/iju.iju_121_21","journal-title":"Indian J Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2025.102952","article-title":"Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: guidelines of the French LUTS Committee (CTMH)","volume":"35","author":"Anract J","year":"2025","unstructured":"Anract J, Klein C, Sarrazin C, et al.. Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: guidelines of the French LUTS Committee (CTMH). Fr J Urol. 2025, 35:102952. 10.1016\/j.fjurol.2025.102952","journal-title":"Fr J Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell JD","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, et al.. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003, 349:2387-98. 10.1056\/NEJMoa030656","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-015-0090-x","article-title":"Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?","volume":"15","author":"Cindolo L","year":"2015","unstructured":"Cindolo L, Pirozzi L, Sountoulides P, et al.. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?. BMC Urol. 2015, 15:96. 10.1186\/s12894-015-0090-x","journal-title":"BMC Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0226-2","article-title":"A retrospective study of treatment persistence and adherence to \u03b1-blocker plus antimuscarinic combination therapies, in men with LUTS\/BPH in the Netherlands","volume":"17","author":"Drake MJ","year":"2017","unstructured":"Drake MJ, Bowditch S, Arbe E, Hakimi Z, Guelfucci F, Amri I, Nazir J. A retrospective study of treatment persistence and adherence to \u03b1-blocker plus antimuscarinic combination therapies, in men with LUTS\/BPH in the Netherlands. BMC Urol. 2017, 17:36. 10.1186\/s12894-017-0226-2","journal-title":"BMC Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20260240","article-title":"The urologists' perspective in management of lower urinary tract symptoms: the questionnaire-based evidence from nationwide survey in India","volume":"14","author":"Wanve D","year":"2026","unstructured":"Wanve D, Khobragade K. The urologists' perspective in management of lower urinary tract symptoms: the questionnaire-based evidence from nationwide survey in India. Int J Res Med Sci. 2026, 14:541-7. 10.18203\/2320-6012.ijrms20260240","journal-title":"Int J Res Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmab070","article-title":"Survey strategies to increase participant response rates in primary care research studies","volume":"38","author":"Booker QS","year":"2021","unstructured":"Booker QS, Austin JD, Balasubramanian BA. Survey strategies to increase participant response rates in primary care research studies. Fam Pract. 2021, 38:699-702. 10.1093\/fampra\/cmab070","journal-title":"Fam Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20240360","article-title":"Expert opinion on the prescription practice of silodosin for treating benign prostatic hyperplasia patients in Indian clinical settings","volume":"11","author":"Manjula S","year":"2024","unstructured":"Manjula S, Kumar KM. Expert opinion on the prescription practice of silodosin for treating benign prostatic hyperplasia patients in Indian clinical settings. Int J Adv Med. 2024, 11:94-8. 10.18203\/2349-3933.ijam20240360","journal-title":"Int J Adv Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03880-y","article-title":"Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones","volume":"56","author":"Abdel-Kader MS","year":"2024","unstructured":"Abdel-Kader MS, Sayed AM, Sayed SM, AbdelRazek M. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones. Int Urol Nephrol. 2024, 56:1605-10. 10.1007\/s11255-023-03880-y","journal-title":"Int Urol Nephrol"},{"key":"ref18","article-title":"A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride","volume":"13","author":"Issa MM","year":"2007","unstructured":"Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care. 2007, 13:S10-6.","journal-title":"Am J Manag Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline Part I-initial work-up and medical management","volume":"206","author":"Lerner LB","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, et al.. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline Part I-initial work-up and medical management. J Urol. 2021, 206:806-17. 10.1097\/JU.0000000000002183","journal-title":"J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169248","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis","volume":"12","author":"Kim HJ","year":"2017","unstructured":"Kim HJ, Sun HY, Choi H, et al.. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS One. 2017, 12:e0169248. 10.1371\/journal.pone.0169248","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03855-1","article-title":"Comparative efficacy and adverse effects of \u03b23-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis","volume":"81","author":"Huang W","year":"2025","unstructured":"Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of \u03b23-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025, 81:1217-27. 10.1007\/s00228-025-03855-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000037","article-title":"Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: a literary review","volume":"15","author":"Wani MM","year":"2021","unstructured":"Wani MM, Sheikh MI, Bhat T, Bhat Z, Bhat A. Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: a literary review. Curr Urol. 2021, 15:153-60. 10.1097\/CU9.0000000000000037","journal-title":"Curr Urol"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.36948\/ijfmr.2025.v07i05.58355","article-title":"Management of benign prostatic hyperplasia with overactive bladder: insights from Indian clinical practice","volume":"7","author":"Gangkak G","year":"2025","unstructured":"Gangkak G, Debnath M, Gupta AK, Agrawal S. Management of benign prostatic hyperplasia with overactive bladder: insights from Indian clinical practice. Int J Multidiscip Res. 2025, 7:1-8.","journal-title":"Int J Multidiscip Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1756287220922425","article-title":"Pharmacology of the lower urinary tract: update on LUTS treatment","volume":"12","author":"Abreu-Mendes P","year":"2020","unstructured":"Abreu-Mendes P, Silva J, Cruz F. Pharmacology of the lower urinary tract: update on LUTS treatment. Ther Adv Urol. 2020, 12:1756287220922425. 10.1177\/1756287220922425","journal-title":"Ther Adv Urol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","volume":"68","author":"Cindolo L","year":"2015","unstructured":"Cindolo L, Pirozzi L, Fanizza C, et al.. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015, 68:418-25. 10.1016\/j.eururo.2014.11.006","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12906","article-title":"Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data","volume":"115","author":"Novara G","year":"2015","unstructured":"Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. BJU Int. 2015, 115:802-14. 10.1111\/bju.12906","journal-title":"BJU Int"},{"key":"ref27","unstructured":"Tadalafil market report 2030. (2026). Accessed. May 20, 2026: https:\/\/www.strategicmarketresearch.com\/market-report\/tadalafil-market."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507070-prescription-trends-in-the-management-of-lower-urinary-tract-symptoms-in-men-an-online-survey-of-indian-urologists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:25:49Z","timestamp":1787718349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507070-prescription-trends-in-the-management-of-lower-urinary-tract-symptoms-in-men-an-online-survey-of-indian-urologists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.115189","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}